Overview

The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The CHB subjects who are cirrhosis, will be randomized to two groups. The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks. The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

Shanghai Nanhui Nanhua Hospital

Treatments:

Adefovir
Adefovir dipivoxil
Entecavir
Interferon-alpha
Peginterferon alfa-2a
Tenofovir